Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC).
Schouten
J T
JT
Whittemore
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage; D017963:Azithromycin / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage; D015725:Fluconazole / Q000008:administration & dosage; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000517:prevention & control*; D017828:Rifabutin / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D014605:Uveitis / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000904:Antibiotics, Antitubercular; D000935:Antifungal Agents; D017828:Rifabutin; D003907:Dexamethasone; D017963:Azithromycin; D004977:Ethambutol; D015725:Fluconazole; D017291:Clarithromycin